We have characterized a series of genetically engineered chimeric human IgG3 and IgG4 anti-dansyl (DNS) antibodies with identical antibody-combining sites but different hinge region amino acid compositions to determine how the hinge region influences Fab fragment segmental flexibility, Clq binding, and complement activation. Our data support the correlation between "upper hinge" length and Fab segmental flexibility; moreover, we confirm that a hinge region is essential for Clq binding and complement activation. However, the hinge length by itself is not sufficient for complement activity in IgG molecules. We have demonstrated that the IgG4 hinge, which imparts restricted segmental flexibility, reduces the ability of IgG3 molecules to activate complement. We also find that the IgG3 hinge region, which imparts greater segmental motion, is not sufficient to create complement activation activity in IgG4 anti-DNS antibodies. Finally, we conclude that (i) segmental motion is correlated with "upper hinge" length, (ii) hinge length and segmental flexibility is not enough to alter complement binding and activation, and (iMi) segmental flexibility does not correlate with proficiency to activate the complement cascade.
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The constant (C) region domains of the four human IgG subclasses have virtually identical amino acid sequences, yet each subclass has different biological effector functionse.g., IgG3 and IgG1 and not IgG2 and IgG4 activate the classical complement cascade (1, 2) in the presence of human complement; chimeric IgG2 will fix rabbit complement (2) . Although the first component of complement, Clq, is believed to bind to the heavy chain constant region 2 (CH2) domain of all IgG subclasses, neither a specific Clq binding site nor a mechanism by which complement is activated is known (3) (4) (5) . Recently, Duncan and Winter (6) have come closest to defining the exact Clq binding site by characterizing the complement activation and Clq binding properties of variant antibody molecules, which they generated by genetically engineering mutations in selected residues in the mouse IgG2b CH2 domain. Duncan and Winter discovered that only three residues, Glu-318, Lys-320, and Lys-322, when altered, affected complement-mediated hemolytic activity and Clq binding. Interestingly, these residues are conserved in all of the human IgGs whether or not they are able to activate complement, suggesting that there must be additional structural requirements for C1 binding and activation.
Isenman et al. (7) showed that although intact human IgG4 does not bind C1, its Fc fragment does; furthermore IgG4 Fc aggregates activate complement. They concluded that the structural features required for C1 binding are present on the IgG4 Fc but that access to this binding site is hindered sterically by the IgG4 Fab "arms" (7, 8) . This model provided a structural basis for the differing effectiveness of different IgG subclasses in activating complement despite the high degree of amino acid identity between the subclasses. Beale and Feinstein (9) proposed that the hinge serves as a spacer, separating the antibody's Fab arms from the Fc, and that hinge length determines Fab segmental flexibility and may affect biological effector functions. They too suggested that the relatively short hinge regions in human IgG2 and IgG4 molecules might place the Fab arms of these antibodies in close proximity to their CH2 domains and hinder C1 binding and activation. The different biological effector functions exhibited by the different immunoglobulin isotypes may be due to the structural variation in the hinge regions. Two variant human IgG1 myeloma proteins, Dob and Lec, have no hinge regions and do not bind C1 (8) or the monocyte Fc receptor (10) .
The human IgG hinge regions in contrast to the C region domains are remarkably diverse (11) . They vary in amino acid sequence and composition as well as length. IgG1, IgG2, and IgG4 have hinge regions consisting of 12-15 amino acids. IgG3 has an extended hinge region, consisting of 62 amino acids, including 21 prolines and 11 cysteines. The IgG3 hinge region can be divided into four segments: one resembles the IgG1 hinge and the other three are identical and unique to IgG3. The "functional" hinge region, deduced from crystallographic studies, extends from amino acid residues 216-237 of the IgG1 H chain (EU numbering; ref. 12) and includes a small segment of the N terminus of the CH2 domain. The hinge can be divided into three regions; the "upper hinge," the "core," and the "lower hinge" (12, 13) . The upper hinge includes the amino acids from the end of CH1 to the first residue in the hinge that restricts motion (generally the first cysteine that forms an inter-heavy-chain bridge). The core hinge contains the inter-H-chain disulfide bridges and a high content of proline. The lower hinge connects to the CH2 domain and includes amino acids in the CH2 domain. Recent studies have demonstrated that upper hinge length correlates with segmental flexibility (2) . In addition, Schneider et al. (14) demonstrated that interactions between structural loops proximal to the hinge region in the CH1 domain and the hinge affect segmental flexibility; however, their data did not distinguish between the contribution of domain-domain interactions and hinge length to Fab segmental flexibility.
In this study, we characterize a number of chimeric human IgG3 and IgG4 molecules with different hinge lengths and amino acid composition. All (15) and to human IgG3 and IgG4 CH in the pSV2AHgpt expression vector (2), respectively; Pvu I linkers were inserted at the Stu I sites between exons in the IgG3 and IgG4 C region genes such that each gene has a single Stu I site converted to a Pvu I site (16) . C region genes containing the desired hinge modification were engineered by using clones with the appropriate Pvu I sites (see Fig. 1 ). The modified IgG3 and IgG4 CH genes were ligated to the DNS VH gene in the pSV2AHgpt vector. The H-and L-chain genes were transfected simultaneously by protoplast fusion into a mouse myeloma cell line (15) . Stable transfectant cell lines were selected by using only G418 (GIBCO) at 1 mg/ml. The level of secretion was between 1 and 5 ,ug per 106 cells per 24 hr. Chimeric anti-DNS antibodies were purified by affinity chromatography as described by Scheider et al. (17) .
Cell Culture. Cell lines were maintained in Iscove's modified Dulbecco's medium (GIBCO) supplemented with 5% fetal calf serum (HyClone), penicillin/streptomycin (10 units of penicillin per ml, 10 ,ug of streptomycin per ml) (GIBCO), 44.6 mM sodium bicarbonate, and 50 ,uM 2-mercaptoethanol.
Complement Depletion Assay. This assay was done as described by Hardy (18) Previous studies (2, 21) indicated that hinge length and Fab segmental flexibility correlate with complement consumption. This correlation is disputed in our current analyses. Two variant IgG3 molecules, as rigid as IgG4, activate complement effectively (see Table 1 ). In contrast, IgG4 with the IgG3 hinge is as flexible as wild-type IgG3 but is unable to activate complement. The inability of wild-type IgG4 antibodies to activate the complement pathway was thought to be due to its restricted hinge region, since aggregated IgG4 Fc fragments activate the complement cascade (7) . However, when we replaced the IgG4 hinge region with the IgG3 hinge, thereby increasing the segmental flexibility and spatial separation between the IgG4 Fab arms and its Fc, the IgG4 antibody was still unable to activate complement. Therefore a long flexible hinge is not sufficient to reveal cryptic complement activation activity in the IgG4 C region domains.
Notably, the IgG3 molecule with the IgG4 hinge is less effective at activating complement than the wild-type IgG3 molecule (see Fig. 2) ; however, this result must be interpreted carefully, because preparations of this antibody con- sist of a mixture of H2L2 tetramers-i.e., tetramers joined by disulfide bridges, as well as HL half-molecules, which form tetramers without covalent bridges. An intact hinge region is required for complement binding and activation. Two hingedeleted human IgG1 myeloma proteins (8), a hinge-deleted mouse IgG2a anti-DNS antibody (14) , the hinge-deleted human IgG3 anti-DNS antibody (described in this report), and reduced-and aklylated antibody do not activate complement. From these studies it is not clear whether it is the hinge region or the formation ofcovalent tetramers that is required. It is conceivable that the disulfide bridged IgG3 molecules with the IgG4 hinge region are as effective at activating complement as wild-type IgG3 molecules, and the noncovalent tetramers do not activate complement at all, resulting in an averaged, reduced effectiveness of the antibody population to activate complement. This interpretation of the data would suggest that the short IgG4 hinge length with its restricted flexibility does not interfere with complement binding or activation by the IgG3 CH2 domain or any other IgG3 structure involved in complement activation.
It is difficult to explain why IgG3 in which the hinge has been further lengthened to 107 amino acids has reduced complement fixing activity. Neither the segmental flexibility of the molecule nor the lower hinge is changed and the Clq binding ability is unaltered. With the lengthened hinge only the core hinge sequence is altered to include six instead of three reiterated hinge exons. This change may influence the relative position of CH1 and the Fc; it is possible that the binding of subsequent complement components is influenced or that the molecule cannot assume an appropriate altered conformation upon Clq binding.
Despite our ability to genetically engineer antibody molecules, the structural basis for antibody-mediated complement activation remains enigmatic. From our analyses of these genetically engineered antibodies, we conclude (i) segmental motion is correlated with upper hinge length; (it) hinge length and segmental flexibility are not enough to effect complement binding and activation; and (iii) segmental flexibility does not correlate with proficiency to activate the complement cascade. In the "aggregation" model of complement activation, C1 binding to antigen-antibody aggregates is enough to activate the complement cascade; in the allostery model, antigen binding is thought to induce a conformational change that enhances Clq activation. In the "distortive" model, antigen binding is proposed to distort the Fc by displacing the Fab arms and exposing a cryptic Clq binding site. Of these three models, the aggregation model of complement activation has had the greatest support, in part because it is difficult to prove that allostery or distortion is involved in triggering antibody-mediated complement activation. It is difficult to specify which model of complement activation reflects our data best; however, it would appear that aggregation and distortion alone are not enough to describe the molecular mechanism of complement activation.
